SM03
As of the edition of 20 October 2026, SM03 is a drug known only by a code name: in active development; acts on CD22.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2017
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD22 | B-cell receptor CD22 | P20273 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| SinoMab BioScience | Lead sponsor of trials | 2012 to now |